"Monumental" is how Ashley E. Webb, MD Assistant Professor, Department of Pediatrics, Division of Child & Adolescent Neurology Neuromuscular Program Director, UTHealth, University of Texas Health ...

More than two years after the Government committed to adding SMA to newborn testing, families are still waiting ...

The tiny zebrafish is helping researchers rapidly determine whether a newborn's genetic mutation is likely to cause spinal ...

Spinal Muscular Atrophy companies are Scholar Rock, Biogen, Astellas Pharma, Alcyone Therapeutics, AndroScience Corporation, Hanugen Theraputics, Voyager Therapeutics ...

DelveInsight’s, “Spinal Muscular Atrophy Pipeline Insight, 2025,” report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in the Spinal muscular atrophy pipeline landscape.

A Prescription Drug User Fee Act target date of September 22, 2025 has been set for the application. The Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License ...

The tiny zebrafish is helping researchers rapidly determine whether a newborn’s genetic mutation is likely to cause spinal ...

The U.S. Food and Drug Administration has approved Itvisma (onasemnogene abeparvovec-brve) for the treatment of spinal muscular atrophy (SMA) in patients 2 years and older with confirmed mutation in ...

Austin, July 25, 2025 (GLOBE NEWSWIRE) -- Spinal Muscular Atrophy Treatment Market Size & Trends: According to SNS Insider, The Spinal Muscular Atrophy Treatment Market was estimated at USD 4.27 ...